Aquestive Therapeutics (AQST) Competitors $7.34 +0.46 (+6.69%) Closing price 04:00 PM EasternExtended Trading$7.52 +0.18 (+2.38%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AQST vs. DNLI, SRPT, ETNB, TVTX, ADPT, NTLA, OCUL, ANIP, VERA, and TWSTShould you be buying Aquestive Therapeutics stock or one of its competitors? The main competitors of Aquestive Therapeutics include Denali Therapeutics (DNLI), Sarepta Therapeutics (SRPT), 89BIO (ETNB), Travere Therapeutics (TVTX), Adaptive Biotechnologies (ADPT), Intellia Therapeutics (NTLA), Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry. Aquestive Therapeutics vs. Its Competitors Denali Therapeutics Sarepta Therapeutics 89BIO Travere Therapeutics Adaptive Biotechnologies Intellia Therapeutics Ocular Therapeutix ANI Pharmaceuticals Vera Therapeutics Twist Bioscience Aquestive Therapeutics (NASDAQ:AQST) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability. Is AQST or DNLI more profitable? Denali Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -147.38%. Aquestive Therapeutics' return on equity of 0.00% beat Denali Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aquestive Therapeutics-147.38% N/A -63.87% Denali Therapeutics N/A -40.79%-36.39% Which has more volatility & risk, AQST or DNLI? Aquestive Therapeutics has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Does the media prefer AQST or DNLI? In the previous week, Denali Therapeutics had 2 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 9 mentions for Denali Therapeutics and 7 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.94 beat Denali Therapeutics' score of 0.49 indicating that Aquestive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings & valuation, AQST or DNLI? Aquestive Therapeutics has higher earnings, but lower revenue than Denali Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAquestive Therapeutics$57.56M12.72-$44.14M-$0.70-10.49Denali Therapeutics$330.53M7.21-$422.77M-$2.80-5.83 Do analysts prefer AQST or DNLI? Aquestive Therapeutics presently has a consensus price target of $10.71, indicating a potential upside of 45.97%. Denali Therapeutics has a consensus price target of $33.50, indicating a potential upside of 105.40%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Denali Therapeutics is more favorable than Aquestive Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aquestive Therapeutics 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.82Denali Therapeutics 1 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 3 Strong Buy rating(s) 3.06 Do insiders & institutionals believe in AQST or DNLI? 32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 7.9% of Aquestive Therapeutics shares are held by insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryDenali Therapeutics beats Aquestive Therapeutics on 11 of the 17 factors compared between the two stocks. Get Aquestive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AQST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AQST vs. The Competition Export to ExcelMetricAquestive TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$731.95M$2.62B$6.04B$10.51BDividend YieldN/A57.77%5.73%4.80%P/E Ratio-10.4922.7985.4427.36Price / Sales12.72557.62515.69196.40Price / CashN/A174.0137.5761.53Price / Book-11.125.5112.426.82Net Income-$44.14M$33.06M$3.32B$276.89M7 Day Performance18.39%0.95%1.01%0.27%1 Month Performance42.80%14.25%10.75%8.31%1 Year Performance50.10%0.85%76.20%35.60% Aquestive Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AQSTAquestive Therapeutics2.7732 of 5 stars$7.34+6.7%$10.71+46.0%+42.1%$731.95M$57.56M-10.49160High Trading VolumeDNLIDenali Therapeutics4.3216 of 5 stars$15.22-1.3%$33.50+120.1%-43.3%$2.25B$330.53M-5.44430News CoverageSRPTSarepta Therapeutics4.614 of 5 stars$23.26+2.7%$39.32+69.0%-82.8%$2.21B$1.90B-26.741,372Analyst ForecastGap UpETNB89BIO2.8772 of 5 stars$14.87+0.1%$25.81+73.6%+87.0%$2.20BN/A-4.1240TVTXTravere Therapeutics2.1104 of 5 stars$26.13+6.0%$34.20+30.9%+49.9%$2.20B$233.18M-12.81460ADPTAdaptive Biotechnologies2.8294 of 5 stars$14.47+0.6%$13.22-8.6%+214.7%$2.19B$178.96M-17.65790News CoverageAnalyst ForecastGap UpNTLAIntellia Therapeutics3.7059 of 5 stars$20.54+2.9%$27.95+36.1%+22.5%$2.14B$57.88M-4.38600Gap UpOCULOcular Therapeutix3.9459 of 5 stars$10.97-3.9%$22.13+101.7%+7.4%$1.99B$63.72M-8.57230ANIPANI Pharmaceuticals3.9363 of 5 stars$92.06+2.7%$97.29+5.7%+51.7%$1.95B$614.38M-119.56600News CoverageVERAVera Therapeutics2.3255 of 5 stars$30.94+2.7%$63.00+103.6%-28.2%$1.92BN/A-8.6440TWSTTwist Bioscience3.8013 of 5 stars$31.85+2.5%$48.90+53.5%-34.5%$1.88B$312.97M-21.97990Gap Up Related Companies and Tools Related Companies DNLI Alternatives SRPT Alternatives ETNB Alternatives TVTX Alternatives ADPT Alternatives NTLA Alternatives OCUL Alternatives ANIP Alternatives VERA Alternatives TWST Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AQST) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquestive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
